Pyoderma Gangrenosum: What Do We Know Now?
- 16 July 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Current Dermatology Reports
- Vol. 7 (3), 147-157
- https://doi.org/10.1007/s13671-018-0224-y
Abstract
No abstract availableKeywords
This publication has 102 references indexed in Scilit:
- Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumabJournal of the American Academy of Dermatology, 2012
- Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutationClinical and Experimental Dermatology, 2012
- Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosumClinical and Experimental Dermatology, 2011
- Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseasesClinical and Experimental Immunology, 2010
- Analgesic effect of locally applied morphine to pyoderma gangrenosumClinical and Experimental Dermatology, 2009
- Expression of MMP‐9, MMP‐10 and TNF‐α and lack of epithelial MMP‐1 and MMP‐26 characterize pyoderma gangrenosumJournal of Cutaneous Pathology, 2007
- Pyoderma gangrenosum – a reviewOrphanet Journal of Rare Diseases, 2007
- The treatment of pyoderma gangrenosum using etanerceptJournal of the American Academy of Dermatology, 2006
- Rheumatoid arthritis‐associated inflammatory leg ulcers: a new treatment for recalcitrant woundsInternational Wound Journal, 2004
- Pyoderma gangrenosum: Classification and managementJournal of the American Academy of Dermatology, 1996